- Conditions
- Advanced/Metastatic Solid Tumor
- Interventions
- KZR-261
- Drug
- Lead sponsor
- Kezar Life Sciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1657–1680
of 4,023
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Tumor, Colorectal Adenocarcinoma
- Interventions
- TST003
- Drug
- Lead sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Portland, Oregon • Dallas, Texas • San Antonio, Texas
- Conditions
- Urothelial Cancer, Bladder Cancer
- Interventions
- Dato-DXd, Carboplatin, Cisplatin, Gemcitabine
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 38
- States / cities
- Fullerton, California • Glendale, California • La Jolla, California + 34 more
- Conditions
- Aging
- Interventions
- Rapamycin, Everolimus, Placebo
- Drug · Other
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 65 Years to 90 Years
- Enrollment
- 194 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Solid Tumors
- Interventions
- Atezolizumab, Selicrelumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Teen Pregnancy, STD Prevention
- Interventions
- The IN•clued program
- Behavioral
- Lead sponsor
- Philliber Research & Evaluation
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 1,401 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Accord, New York
- Conditions
- Advanced Solid Tumor
- Interventions
- QTX3046, Cetuximab
- Drug · Combination Product
- Lead sponsor
- Quanta Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Grand Rapids, Michigan • Durham, North Carolina • Houston, Texas + 2 more
- Conditions
- Esophageal Stenosis, Stent Migration, Suture, Complication
- Interventions
- Esophageal stent placement
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Sickle Cell Disease, Pregnancy Related
- Interventions
- Prophylactic Transfusion Intervention group: Transfusion, Control group
- Biological · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Solid Tumors, KRAS Mutation
- Interventions
- BI 1823911, BI 1701963, Midazolam
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 3
- States / cities
- New York, New York • Dallas, Texas • Houston, Texas
- Conditions
- Cerebral Neurological Illness
- Interventions
- Railroad Test, Swamp Test, Presidents Recognition Test, Judgment of Line Orientation, Symbol Span subtest of the Wechsler Memory Scale-IV, Information subtest of the Wechsler Adult Intelligence Scale-IV:, Digit Span subtest of the Wechsler Adult Intelligence Scale-I, Reading subtest of the Wide Range Achievement Test, Symbol Digit Modalities Test:, Dot Counting Test
- Diagnostic Test
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 137 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cancer, Fatigue
- Interventions
- Physical Activity/Physical Functioning, Quality of Life
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Atopic Dermatitis
- Interventions
- APG777, Placebo
- Drug
- Lead sponsor
- Apogee Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 29
- States / cities
- Fountain Valley, California • Los Angeles, California • San Diego, California + 25 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- SC-002
- Drug
- Lead sponsor
- Stemcentrx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 4
- States / cities
- Ann Arbor, Michigan • St Louis, Missouri • New York, New York + 1 more
- Conditions
- Healthy Participants
- Interventions
- S-740792 Suspension, Midazolam, Placebo, S-740792 Tablet
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Glioma
- Interventions
- Rhenium Liposome Treatment
- Drug
- Lead sponsor
- Cerenome
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 4
- States / cities
- Manhasset, New York • Columbus, Ohio • Dallas, Texas + 1 more
- Conditions
- Delayed Graft Function, Other Complication of Kidney Transplant
- Interventions
- I5NP, Saline
- Drug
- Lead sponsor
- Quark Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 374 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 22 more
- Conditions
- Gaucher Disease Type 1, Gaucher Disease Type 3
- Interventions
- venglustat (GZ402671), imiglucerase
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Dallas, Texas • Fairfax, Virginia
- Conditions
- Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Colorectal Cancer, Sarcoma
- Interventions
- NKTR-262, bempegaldesleukin, nivolumab
- Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • La Jolla, California • Tampa, Florida + 11 more
- Conditions
- Pigmented Villonodular Synovitis, PVNS, Giant Cell Tumor of the Tendon Sheath, GCCTS, Tenosynovial Giant Cell Tumor Localized or Diffused Type, GCTS
- Interventions
- MCS110, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 7
- States / cities
- San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 4 more
- Conditions
- Renal Impairment, Healthy Volunteers
- Interventions
- TAK-279
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • Chicago, Illinois
- Conditions
- Toothbrushing, Dental Plaque, Parent-Child Relations, Oral Hygiene, Dental Caries
- Interventions
- Drawing Incentive
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 6 Months to 47 Months
- Enrollment
- 244 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma
- Interventions
- RO7293583, Tocilizumab, Obinutuzumab, Adalimumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Tetrathiomolybdate
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, New York